Check-Cap Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Lontini
- Full Time Employees
- 85
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Check-Cap Building Isfiya Israel 30090
- IPO Date
- Mar 4, 2015
- CIK
- 0001610590
- Website
- check-cap.com
- Similar Companies
- Business
- Check-Cap Ltd. is a medical technology company specializing in the development and commercialization of ingestible imaging capsules for gastrointestinal diagnostics. Its core products include the Check-Cap C-Scan system, an ingestible capsule combined with an FDA-cleared external detection device, designed to provide a radiation-free, non-invasive alternative to conventional colonoscopy for colorectal cancer screening. The system enables early detection of colorectal abnormalities by capturing high-resolution images as the capsule passes through the gastrointestinal tract. Check-Cap’s offerings focus on improving patient compliance and providing accurate, safe, and convenient diagnostic procedures primarily for colorectal cancer screening. The company operates primarily in Israel and internationally, targeting healthcare providers and diagnostic centers. Founded in 2007 and headquartered in Israel, Check-Cap has advanced its clinical pipeline and regulatory milestones to commercialize its imaging capsule system. Recent major developments include advancing the commercialization of its FDA-approved C-Scan system and expanding clinical trials to broaden adoption in key markets. Check-Cap continues to secure strategic partnerships and funding to support regulatory approvals and market penetration. These efforts reflect a strategic focus on accelerating the availability of its technology in the US and global markets, enhancing its position in the medical diagnostics industry. The company is positioned within the medical devices industry, specifically in the healthcare diagnostics segment, targeting hospitals, clinics, and colorectal cancer screening programs worldwide. Check-Cap leverages proprietary technology in ingestible imaging capsules to address limitations in current colorectal cancer screening methods, aiming to improve early detection rates and patient outcomes. No recent name changes or major reorganizations have been reported, with ongoing efforts focused on operational scaling, regulatory approvals, and expanding its product portfolio within gastrointestinal diagnostics. Check-Cap Ltd.’s strategic direction underscores its commitment to innovation in non-invasive diagnostic imaging, leveraging advances in capsule technology and digital imaging, with operations centered in Israel and outreach into key international healthcare markets. The company’s specialized technology, regulatory progress, and ongoing strategic collaborations support its mission to transform colorectal cancer screening and gastrointestinal diagnostics through safer, patient-friendly solutions.
Accuray (NASDAQ:ARAY) & Check-Cap (NASDAQ:CHEK) Critical Analysis
MBody AI ($CHEK) Secures 98% Shareholder Approval to Become Leading Nasdaq Embodied AI Company
MBody AI ($CHEK) Expands Global Leadership in Embodied AI With Major Wins
RETRANSMISSION: Check-Cap and MBody AI Advance Toward Closing Transformational Merger
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
MediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Why Is Check-Cap (CHEK) Stock Up 44% Today?
Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
CHECK- CAP BOARD MEMBER'S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTAL
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEES
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEES
Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting
Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Check-Cap Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Check-Cap Reports Second Quarter 2023 Financial Results
SYMETRYX CORP INCREASES NON-BINDING OFFER TO ACQUIRE CHECK-CAP TO $4.60 PER SHARE
3 Medical Instruments Stocks With Potential to Outperform